Immunovant Stock (NASDAQ:IMVT)
Previous Close
$31.61
52W Range
$14.32 - $36.28
50D Avg
$28.69
200D Avg
$24.08
Market Cap
$6.40B
Avg Vol (3M)
$1.85M
Beta
0.79
Div Yield
-
IMVT Company Profile
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.
IMVT Performance
Peer Comparison
| Ticker | Company |
|---|---|
| VKTX | Viking Therapeutics, Inc. |
| CRNX | Crinetics Pharmaceuticals, Inc. |
| RARE | Ultragenyx Pharmaceutical Inc. |
| ACAD | ACADIA Pharmaceuticals Inc. |
| PRAX | Praxis Precision Medicines, Inc. |
| SLNO | Soleno Therapeutics, Inc. |
| KYMR | Kymera Therapeutics, Inc. |
| NAMS | NewAmsterdam Pharma Company N.V. |
| DYN | Dyne Therapeutics, Inc. |
| AKRO | Akero Therapeutics, Inc. |